FSD Pharma Inc. (HUGE): Price and Financial Metrics
HUGE Stock Summary
- HUGE has a market capitalization of $15,947,114 -- more than approximately merely 3.49% of US stocks.
- HUGE's went public 1.19 years ago, making it older than just 0.52% of listed US stocks we're tracking.
- Revenue growth over the past 12 months for FSD Pharma Inc comes in at 187.49%, a number that bests 96.83% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to FSD Pharma Inc are AMK, AVCO, ASM, SHWZ, and TRC.
- To check out FSD Pharma Inc's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001771885.
HUGE Stock Price Chart Interactive Chart >
HUGE Price/Volume Stats
|Current price||$1.88||52-week high||$14.00|
|Prev. close||$1.94||52-week low||$1.28|
|Day high||$1.88||Avg. volume||3,773,974|
|50-day MA||$2.16||Dividend yield||N/A|
|200-day MA||$2.40||Market Cap||36.02M|
FSD Pharma Inc. (HUGE) Company Bio
FSD Pharma Inc., through its subsidiary, FV Pharma Inc., produces medical cannabis in Canada. The company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based treatments for central nervous system disorders and autoimmune diseases of the skin, GI tract, and musculoskeletal system, such as chronic pain. FSD Pharma Inc. has strategic alliance agreements with SciCann Therapeutics Inc., CannTab Therapeutics, and Solarvest BioEnergy Inc. The company was founded in 1998 and is headquartered in Toronto, Canada.
HUGE Latest News Stream
|Loading, please wait...|
HUGE Latest Social Stream
View Full HUGE Social Stream
Latest HUGE News From Around the Web
Below are the latest news stories about FSD Pharma Inc that investors may wish to consider to help them evaluate HUGE as an investment opportunity.
On Tuesday, March 30, 2021, Anthony Durkacz, a founding director and member of the group of concerned shareholders, which also includes founding shareholder Zeeshan Saeed, (the "Concerned Shareholders") of FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9) (the "Company" or "FSD") received a Notice of Appeal from FSD (the "Appeal") of the March 5, 2021 decision (the "Decision") of the Ontario Superior Court of Justice (Commercial List) (the "Court"). The Decision, which resulted from an application to the Court brought by Mr. Durkacz on behalf of the Concerned Shareholders, ordered the Company to accelerate the date of its previously called annual shareholders' meeting (the "Meeting") from June 29, 2021 to May 14, 2021, retain an independent chair to preside over the Meeting and prev...
FSD Pharma (HUGE) used to grow and process medical cannabis in Canada to help fund their research efforts in cannabinoids and the human endo-cannabinoid system. Although the company did not continue in their efforts to grow and process cannabis, they did find a chemical compound that reacts with the CB2...
FSD Pharma (HUGE) soars 56% premarket after entering into a license agreement with Innovet Italia S.R.L., under which Innovet granted the Company a license to use ultramicronized-palmitoylethanolamide to develop FDA approved veterinary drugs for the treatment of gastro-intestinal diseases in Canine and Feline (Dogs and Cats). The agreement provides that the Company...
HUGE stock is screaming for the top after the company announced a licensing agreement. This could be a short squeeze.
Gainers FSD Pharma Inc. (NASDAQ: HUGE) shares rose 50.7% to $3.12 in pre-market trading as the company entered into a license agreement to develop FDA …
HUGE Price Returns
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!